Endo Targets Actavis Over Generic Versions Of Opana

Law360, New York (December 12, 2012, 9:21 PM EST) -- Endo Pharmaceuticals Inc. on Tuesday launched patent infringement and false advertising suits against Actavis Inc. in New York and New Jersey federal courts, respectively, in yet another effort to keep copycat versions of its Opana ER painkiller from coming to market.

While Endo and Actavis — which was bought by generics giant Watson Pharmaceuticals Inc. earlier this year for $5.65 billion — settled an infringement case in 2009 that allowed Actavis to sell a generic version of Opana ER, that agreement doesn't cover the three patents...
To view the full article, register now.